BioCentury
ARTICLE | Clinical News

Takeda discontinues alisertib trial

May 14, 2015 1:56 AM UTC

Takeda Pharmaceutical Co Ltd. (Tokyo:4502) discontinued a Phase III trial of alisertib ( MLN8237) to treat relapsed or refractory peripheral T cell lymphoma (PTCL). Takeda said an interim analysis showed the trial was unlikely to meet the primary endpoint of superior progression-free survival (PFS) vs. standard of care. ...